肥胖男性的促性腺功能减退

Q3 Medicine

Obesity and Metabolism Pub Date : 2009-09-15 DOI:10.14341/2071-8713-5243

L. Savel'eva, R. Rozhivanov, B. O. Shurdumova, V. Fadeev

{"title":"肥胖男性的促性腺功能减退","authors":"L. Savel'eva, R. Rozhivanov, B. O. Shurdumova, V. Fadeev","doi":"10.14341/2071-8713-5243","DOIUrl":null,"url":null,"abstract":"Objective: to evaluate the preavalence and characteristics of hypogonadism in obese man. Research and Methods: Thestudy was performed in 31 obese man (aged 33 [22;44], BMI 40 [34,4;44,0]. Measurements during the study: chemistry panel, testosteroa and LH levels, immunoreactive insulin, HOMA index calculation. Statistically significant difference w as considered as p < 0,05. Results. Hypogonadism preavalence was 80,6%. The hypogonadism prevalence and testosterone level was more depended on age and obesity but less on duration. 100 % risk of hypogonadism w as observed in heavily obese patients. There w as no increase of LH levels. In man with low testosterone lev els HOMA index w as significantly higher со mpared to healthy subjects. Conclusion: The prevalence of normogonadotropic hypogonadism in obese men is extremely high and it represents an evidence of functional disorder of hypophyseal gonadal system. Thedecrease of testosterone levels is age-coinciding, but it is more pronounced in obese nan.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":"97 1","pages":"39-42"},"PeriodicalIF":0.0000,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"Normogonadotropic hypogonadism in men with obesity\",\"authors\":\"L. Savel'eva, R. Rozhivanov, B. O. Shurdumova, V. Fadeev\",\"doi\":\"10.14341/2071-8713-5243\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: to evaluate the preavalence and characteristics of hypogonadism in obese man. Research and Methods: Thestudy was performed in 31 obese man (aged 33 [22;44], BMI 40 [34,4;44,0]. Measurements during the study: chemistry panel, testosteroa and LH levels, immunoreactive insulin, HOMA index calculation. Statistically significant difference w as considered as p < 0,05. Results. Hypogonadism preavalence was 80,6%. The hypogonadism prevalence and testosterone level was more depended on age and obesity but less on duration. 100 % risk of hypogonadism w as observed in heavily obese patients. There w as no increase of LH levels. In man with low testosterone lev els HOMA index w as significantly higher со mpared to healthy subjects. Conclusion: The prevalence of normogonadotropic hypogonadism in obese men is extremely high and it represents an evidence of functional disorder of hypophyseal gonadal system. Thedecrease of testosterone levels is age-coinciding, but it is more pronounced in obese nan.\",\"PeriodicalId\":37832,\"journal\":{\"name\":\"Obesity and Metabolism\",\"volume\":\"97 1\",\"pages\":\"39-42\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity and Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14341/2071-8713-5243\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/2071-8713-5243","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 8

摘要

目的:了解肥胖男性性腺功能减退的患病率及特点。研究与方法:研究对象为31名33岁[22;44]，BMI为40[34,4;44,0]的肥胖男性。研究期间的测量:化学面板，睾酮和LH水平，免疫反应性胰岛素，HOMA指数计算。p < 0.05认为差异有统计学意义。结果。性腺功能减退症患病率为806%。性腺功能减退的患病率和睾酮水平与年龄和肥胖的关系更大，而与病程的关系较小。在重度肥胖患者中，性腺功能减退的风险为100%。黄体生成素水平未见升高。睾酮水平低的男性HOMA指数明显高于健康人群。结论:肥胖男性正常促性腺功能低下患病率极高，是垂体性腺系统功能障碍的证据。睾丸激素水平的下降与年龄一致，但在肥胖男性中更为明显。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Normogonadotropic hypogonadism in men with obesity

Objective: to evaluate the preavalence and characteristics of hypogonadism in obese man. Research and Methods: Thestudy was performed in 31 obese man (aged 33 [22;44], BMI 40 [34,4;44,0]. Measurements during the study: chemistry panel, testosteroa and LH levels, immunoreactive insulin, HOMA index calculation. Statistically significant difference w as considered as p < 0,05. Results. Hypogonadism preavalence was 80,6%. The hypogonadism prevalence and testosterone level was more depended on age and obesity but less on duration. 100 % risk of hypogonadism w as observed in heavily obese patients. There w as no increase of LH levels. In man with low testosterone lev els HOMA index w as significantly higher со mpared to healthy subjects. Conclusion: The prevalence of normogonadotropic hypogonadism in obese men is extremely high and it represents an evidence of functional disorder of hypophyseal gonadal system. Thedecrease of testosterone levels is age-coinciding, but it is more pronounced in obese nan.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Obesity and Metabolism Medicine-Internal Medicine

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Journal "Obesity and Metabolism" is a multidisciplinary forum for clinical and applied research in the field of biochemistry, physiology, pathophysiology, genetics, nutrition, as well as molecular, metabolic, psychological and epidemiological aspects of obesity and metabolism. The main subject "Metabolism" reviewed in the journal, includes fat, carbohydrate, protein, bone, fluid and electrolyte and other types of metabolism in the spectrum of pathology of the endocrine system. The priority direction of Journal "Obesity and Metabolism" is publishing modern high-quality original research on the effectiveness of new and existing treatments in any aspect of metabolic and endocrine diseases. Pre-clinical pharmacology, pharmacokinetics studies, meta-analyzes, addressed to drug safety and tolerance are also welcome for publication in the journal "Obesity and metabolism." Journal "Obesity and Metabolism" announces review articles that are balanced, clear and offer the reader a modern and critical analysis of the literature on the subject of the magazine. Case reports, and lecture materials are also published for highlighting for practitioners new approaches to diagnosis and treatment of patients with metabolic disorders and obesity.